ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

ClinicalTrials.gov ID: NCT05316701

Public ClinicalTrials.gov record NCT05316701. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft

Study identification

NCT ID
NCT05316701
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Orca Biosystems, Inc.
Industry
Enrollment
187 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 20, 2022
Primary completion
Jul 14, 2024
Completion
Jun 30, 2026
Last update posted
Mar 3, 2026

2022 – 2026

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
City of Hope Duarte California 91010
Ronald Reagan UCLA Medical Center Los Angeles California 90095
UC Davis Sacramento California 95817
Stanford Health Care Stanford California 94305
Colorado Blood Cancer Institute Denver Colorado 80218
University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center Miami Florida 33136
Moffitt Cancer Center Tampa Florida 33612
Winship Cancer Institute - Emory University Atlanta Georgia 30322
University of Chicago Chicago Illinois 60637
Massachusetts General Hospital Boston Massachusetts 02114
University of Michigan Health System - Michigan Medicine Ann Arbor Michigan 48109
Weill Cornell Medicine - New York-Presbyterian Hospital New York New York 10021
Memorial Sloan Kettering Cancer Center New York New York 10065
Cleveland Clinic Cleveland Ohio 44195
OU Health Stephenson Cancer Center Oklahoma City Oklahoma 73104
Oregon Health & Sciences University - Knight Cancer Institute Portland Oregon 97239
Vanderbilt University Nashville Tennessee 37232
Sarah Cannon Research Institute Nashville Tennessee 37239
University of Utah Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05316701, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 3, 2026 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05316701 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →